Publications
Explore publications relevant to our product candidates and technologies
This page contains links to third‑party websites and materials that are not owned, controlled, or maintained by Oculis. These links are provided for informational purposes only and are not incorporated by reference into any of Oculis’s SEC filings. Oculis does not endorse, adopt, or make any representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third‑party content, and has no obligation to update such content. References and links to scientific publications may include data and information relating to product candidates that are investigational and not approved by any regulatory authority for the indications discussed. These materials are intended solely to provide scientific information to healthcare and research professionals and are not intended to promote any product, make efficacy or safety claims, or compare products. The publications may present preliminary findings, which are subject to further validation. Nothing on this page constitutes medical advice; patients should consult a qualified healthcare professional regarding diagnosis and treatment decisions. Any views, opinions, findings, or conclusions expressed in third‑party materials are those of the author(s) and do not necessarily reflect the views of Oculis.
Privosegtor
A Phase 1 Randomized Study on The Safety and Pharmacokinetics of OCS-05, a Neuroprotective Disease Modifying Treatment for Acute Optic Neuritis and Multiple Sclerosis
Axonal and Myelin Neuroprotection by The Peptoid BN201 in Brain Inflammation
OCS-01
OCS-01 (Novel Topical Dexamethasone Formulation) in Inflammation and Pain Post Cataract Surgery: A Randomized, Double-Masked, Vehicle-Controlled Study
Topical Treatment of Diabetic Macular Edema Using Dexamethasone Ophthalmic Suspension: A Randomized, Double-Masked, Vehicle-Controlled Study
Topical Dexamethasone-Cyclodextrin Microparticle Eye Drops For Diabetic Macular Edema
Topical Dexamethasone-Cyclodextrin Nanoparticle Eye Drops for Non-Infectious Uveitic Macular Oedema and Vitritis – A Pilot Study
Topical Dexamethasone γ-Cyclodextrin Nanoparticle Eye Drops Increase Visual Acuity and Decrease Macular Thickness in Diabetic Macular Oedema
Licaminlimab
Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase 2 Study
Efficacy and Safety of OCS-02 a novel, potent, topical TNFα antibody in acute anterior uveitis (AAU): a phase 2 study
OPTIREACH®
Topical Dexamethasone Delivery to The Retina: An Aqueous Cyclodextrin-Based Microsuspension
Topical Drug Delivery to The Retina: Obstacles and Routes to Success
Angiotensin Receptor Blockers in Cyclodextrin Nanoparticle Eye Drops: Ocular Pharmacokinetics and Pharmacologic Effect on Intraocular Pressure
Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits
Topical Drug Delivery to The Posterior Segment of The Eye: Thermodynamic Considerations
Our potential to transform patients’ lives through visionary innovation